Klivira
Request demo

Optimizing Aetna Tepezza Prior Authorization Workflows

Navigating Aetna Tepezza prior authorization can be complex due to its specialty drug status and Aetna's varied submission channels, but Klivira streamlines this critical process.

For revenue cycle directors and prior authorization coordinators, efficient management of high-volume specialty drug PAs like Tepezza is crucial for patient access and financial health. Understanding Aetna's specific requirements, from submission pathways to clinical criteria, is key to minimizing delays and denials for patients requiring this vital medication.

Understanding Tepezza and Aetna's Prior Authorization Landscape

Tepezza (teprotumumab-trbw) is a high-volume prior authorization target, critical for patients with Thyroid Eye Disease across commercial, Medicare Advantage, and Medicaid managed care plans. As a specialty infusion, its approval process with Aetna, a national insurer under CVS Health, necessitates a clear understanding of specific medical benefit pathways and utilization management criteria.

Aetna's Prior Authorization Submission Channels for Specialty Medications

For specialty injectable and infused medications like Tepezza, Aetna typically routes medical-benefit precertification requests through the Availity provider portal, their primary multi-payer workspace. Additionally, Aetna supports X12 278 transactions via clearinghouses for applicable procedure categories, offering an electronic submission alternative for integrated workflows.

Navigating Aetna's Medical Necessity Criteria for Tepezza

Aetna publishes its medical-necessity criteria, including those for specialty medications, in its public Clinical Policy Bulletins (CPBs). These CPBs are versioned, dated, and serve as the canonical identifier for Aetna's utilization management policies, outlining the specific clinical indications and documentation required for Tepezza approval.

Prior Authorization Turnaround Times and Compliance

Aetna's prior authorization decision timeframes are influenced by state-mandated minimums for commercial plans and NCQA Utilization Management accreditation standards. For Medicare Advantage and Medicaid managed-care lines, Aetna is an impacted payer under CMS-0057-F, which mandates 72-hour decisions for standard PA requests and 24-hour for expedited requests, with phased compliance through 2027.

Electronic Prior Authorization (ePA) for Aetna Submissions

While Aetna utilizes CoverMyMeds and Surescripts for retail pharmacy ePA workflows, medical-benefit ePA, particularly for infused specialty drugs like Tepezza, can be more fragmented. Klivira integrates directly with provider portals and supports X12 278 transactions, facilitating efficient electronic submission regardless of the specific medical-benefit ePA infrastructure.

Common Denial Reasons and Appeal Pathways for Tepezza

Denials for Tepezza prior authorizations under Aetna often stem from reasons such as insufficient documentation of medical necessity, failure to meet step therapy requirements if applicable, or off-label use without compendium support. Aetna's appeal pathway typically includes reconsideration, peer-to-peer review, and formal appeals, with expedited options for urgent care needs.

Frequently asked questions

How do I submit a prior authorization request for Tepezza to Aetna?

For specialty infused medications like Tepezza, Aetna typically directs medical-benefit prior authorization requests through the Availity provider portal. You can also submit X12 278 transactions via clearinghouses for eligible procedure categories, offering an integrated electronic submission method.

Where can I find Aetna's medical necessity criteria for Tepezza?

Aetna publishes its medical necessity criteria, including those for specialty drugs, in its public Clinical Policy Bulletins (CPBs). These documents outline the specific clinical indications and required documentation for approval, and are accessible via Aetna's CPB library.

What are the expected turnaround times for Aetna Tepezza prior authorizations?

Turnaround times vary based on the Aetna plan type and state regulations. Commercial plans adhere to state-mandated minimums and NCQA standards. For Medicare Advantage and Medicaid managed-care plans, Aetna is subject to CMS-0057-F, requiring 72-hour decisions for standard requests and 24-hour for expedited.

What are common reasons for Aetna Tepezza prior authorization denials?

Common denial reasons for specialty medications like Tepezza include insufficient documentation of medical necessity, failure to meet specific clinical criteria outlined in CPBs, or not satisfying step therapy requirements if they apply. Denials are communicated via X12 835/277 or portal updates.

Does Aetna support electronic prior authorization (ePA) for Tepezza?

Aetna supports electronic submissions for medical-benefit prior authorizations via the Availity portal and X12 278 transactions. While pharmacy-benefit ePA uses partners like CoverMyMeds and Surescripts, the medical-benefit ePA landscape for infused drugs like Tepezza is more varied, making direct integration crucial.

How can I appeal an Aetna prior authorization denial for Tepezza?

Aetna's appeal process generally involves multiple levels, including reconsideration, peer-to-peer review, and formal appeals. Expedited appeal pathways are available for urgent care needs. The specific appeal steps and timely-filing windows are detailed in Aetna's provider manual.

Related coverage

Other tepezza prior authorization by payer

Other tepezza prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo